299 related articles for article (PubMed ID: 34859619)
21. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.
Lee T; Sawicki GS; Altenburg J; Millar SJ; Geiger JM; Jennings MT; Lou Y; McGarry LJ; Van Brunt K; Linnemann RW
J Cyst Fibros; 2023 May; 22(3):402-406. PubMed ID: 36581485
[TBL] [Abstract][Full Text] [Related]
22. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
[TBL] [Abstract][Full Text] [Related]
23. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
24. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
[TBL] [Abstract][Full Text] [Related]
25. Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.
Park J; Walsh A; Kerr S; Woodland C; Southward S; Deakin M; Senniappan S; Thursfield R
Horm Res Paediatr; 2024; 97(1):94-98. PubMed ID: 37040724
[TBL] [Abstract][Full Text] [Related]
26. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
27. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One
Goralski JL; Hoppe JE; Mall MA; McColley SA; McKone E; Ramsey B; Rayment JH; Robinson P; Stehling F; Taylor-Cousar JL; Tullis E; Ahluwalia N; Chin A; Chu C; Lu M; Niu T; Weinstock T; Ratjen F; Rosenfeld M
Am J Respir Crit Care Med; 2023 Jul; 208(1):59-67. PubMed ID: 36921081
[No Abstract] [Full Text] [Related]
29. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
30. Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation.
Cheng A; Baker O; Hill U
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35236685
[TBL] [Abstract][Full Text] [Related]
31. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
[TBL] [Abstract][Full Text] [Related]
32. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
[TBL] [Abstract][Full Text] [Related]
33. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
34. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
[TBL] [Abstract][Full Text] [Related]
35. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
[No Abstract] [Full Text] [Related]
36. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
[TBL] [Abstract][Full Text] [Related]
37. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis.
Donaldson SH; Corcoran TE; Pilewski JM; Mogayzel P; Laube BL; Boitet ER; Harris ES; Ceppe A; Edwards LJ; Zeman K; Wu J; Esther CR; Nichols DP; Bennett WD; Rowe SM
J Cyst Fibros; 2024 Jan; 23(1):155-160. PubMed ID: 37845149
[TBL] [Abstract][Full Text] [Related]
38. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
Smith S; Borchardt M
J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
[No Abstract] [Full Text] [Related]
39. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
Nathan N; Thouvenin G; Dubern B; Corvol H
Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
[No Abstract] [Full Text] [Related]
40. Elexacaftor/Ivacaftor/Tezacaftor: First Approval.
Hoy SM
Drugs; 2019 Dec; 79(18):2001-2007. PubMed ID: 31784874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
